According to a recent LinkedIn post from Viome, the company is using its “Two PhDs on a Pod” series to emphasize the role of RNA expression over DNA in understanding chronic disease. The post contrasts static genetic information with dynamic RNA activity, suggesting that factors like environment, nutrition, sleep, and stress may drive disease expression.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights Viome’s positioning around RNA, gene expression, and microbiome analysis as potentially more actionable than traditional DNA-focused approaches. For investors, this content underscores the company’s effort to differentiate its precision health platform within the diagnostics and wellness markets, which could support demand for its testing and subscription services if the scientific framing gains broader clinical and consumer traction.
By featuring its founding CSO and CTO as thought leaders, Viome appears to be building brand authority around RNA-based insights and “upstream” disease prevention. This strategy may help the company compete against established genetic testing players by shifting the narrative away from genetic determinism, potentially expanding its addressable market among consumers and partners looking for more dynamic biomarkers.
The emphasis on chronic disease, healthcare costs, and “expensive misconceptions” in current care models suggests Viome is targeting long-term opportunities in value-based and preventive healthcare. If healthcare providers, payers, or employers increasingly seek tools that monitor gene expression and microbiome changes, Viome’s focus on RNA could support future commercial partnerships, recurring revenue streams, and a stronger strategic position in precision health.